Oculis Holding AG (OCS)

NGM – Real vaqt narxi. Valyuta: USD

30.41

-2.24 (-6.86%)

Yopilishda: May 12, 2026, 4:00 PM EDT

30.41

0.00 (0.00%)

Bozor oldidan: May 13, 2026, 8:10 AM EDT

11.05.2026

Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates

Oculis Holding AG (OCS) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.77 per share a year ago.

11.05.2026

Oculis Reports Q1 2026 Financial Results and Provides Company Update

ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026 Licaminlimab PREDICT-1 Trial in Active Site Recruitment Phase, Pioneering a Genotype-Driven Path to Precision Medicine in Dry Eye Disease Privosegtor Regulatory Path Cleared via FDA SPA; PIONEER-1 Phase 3 Trial Advances with Ongoing Site Activation Cash, cash equivalents, and short-term investments of $277.6 million as of March 31, 2026, providing cash runway into 2H 2029 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the first quarter ended March 31, 2026, and provided an overview of the Company's progress. Riad Sherif, M.D.

07.05.2026

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

ZUG, Switzerland, May 7 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) regarding PIONEER-1, the first registrational trial within the PIONEER Program evaluating Privosegtor for the treatment of optic neuritis (ON). This formal FDA agreement confirms the design and planned analysis of the PIONEER-1 study are adequate to address the objectives necessary to support a future NDA submission, subject to a successful trial outcome and FDA review of the complete submission.

05.05.2026

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) management Oculis is on track to report topline results in June 2026 from DIAMOND Phase 3 registrational trials with OCS-01, which aims to be the first eye drop therapy for DME ZUG, Switzerland, May 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announces that the latest findings of the DME AWARE Delphi study were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting. DME affects mainly a working-age population and is typically diagnosed at an average age of 52 years.1, 2 One year following diagnosis, 60% of patients are not treated2a while we know that delaying treatment is not beneficial for patients as it represents a missed opportunity to fully regain vision.

01.05.2026

Lumentum Q3 Earnings Loom: Buy or Sell the Stock Ahead of Results?

LITE's fiscal Q3 outlook is likely to have pointed to surging AI-driven demand and strong revenue growth, but premium valuation raises the key question for investors.

01.05.2026

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

ZUG, Switzerland, May 01, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that it will be highlighting the transformative potential of its late-stage pipeline, recent development milestones achieved and key areas of unmet medical needs at the Eyecelerator and Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting.

21.04.2026

Oculis Publishes Invitation to the Annual General Meeting

ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), today published the invitation to the 2026 Annual General Meeting, which will be held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 6:00 a.m. EDT / 10:00 a.m. GMT / 12:00 p.m. CEST.

Videolar

No Data

There is no data to display

Press-relizlar

11.05.2026

Oculis Reports Q1 2026 Financial Results and Provides Company Update

07.05.2026

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

05.05.2026

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

21.04.2026

Oculis Holding AG (OCS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Oculis Holding AG (OCS)

Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates

Oculis Reports Q1 2026 Financial Results and Provides Company Update

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Lumentum Q3 Earnings Loom: Buy or Sell the Stock Ahead of Results?

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting

Videolar

No Data

Press-relizlar

Oculis Reports Q1 2026 Financial Results and Provides Company Update

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting

Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates

Oculis Reports Q1 2026 Financial Results and Provides Company Update

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Lumentum Q3 Earnings Loom: Buy or Sell the Stock Ahead of Results?

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting

Videolar

No Data

Press-relizlar

Oculis Reports Q1 2026 Financial Results and Provides Company Update

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting

Search stocks

Oculis Holding AG (OCS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Oculis Holding AG (OCS)

Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates

Oculis Reports Q1 2026 Financial Results and Provides Company Update

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Lumentum Q3 Earnings Loom: Buy or Sell the Stock Ahead of Results?

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting

Videolar

No Data

Press-relizlar

Oculis Reports Q1 2026 Financial Results and Provides Company Update

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting

Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates

Oculis Reports Q1 2026 Financial Results and Provides Company Update

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Lumentum Q3 Earnings Loom: Buy or Sell the Stock Ahead of Results?

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting

Videolar

No Data

Press-relizlar

Oculis Reports Q1 2026 Financial Results and Provides Company Update

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting